MediPharm Labs (FRA:MLZ) Other Current Receivables: €0.35 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MediPharm Labs Other Current Receivables?

MediPharm Labs FRA:MLZ Other Current Receivables is €0.35 Mil as of Jun. 2026. The stock has 4 warning signs investors should review.

MediPharm Labs's Other Current Receivables for the quarter that ended in Jun. 2026 was €0.35 Mil.

MediPharm Labs's quarterly Other Current Receivables increased from Dec. 2025 (€0.47 Mil) to Mar. 2026 (€0.48 Mil) but then stayed the same from Mar. 2026 (€0.48 Mil) to Jun. 2026 (€0.35 Mil).

MediPharm Labs's annual Other Current Receivables increased from Dec. 2023 (€0.24 Mil) to Dec. 2024 (€0.43 Mil) and increased from Dec. 2024 (€0.43 Mil) to Dec. 2025 (€0.47 Mil).

MediPharm Labs Other Current Receivables Related Terms

MediPharm Labs Other Current Receivables Historical Data

* Premium members only.

The historical data trend for MediPharm Labs's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediPharm Labs Other Current Receivables Chart

MediPharm Labs Annual Data
Trend Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 1.11 0.46 0.24 0.43 0.47

MediPharm Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.68 0.47 0.48 0.35

MediPharm Labs Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.35 Mil mean?
MediPharm Labs (FRA:MLZ) has a Other Current Receivables of €0.35 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on MediPharm Labs and its competitors.
Is MediPharm Labs' Other Current Receivables too high?
MediPharm Labs' current Other Current Receivables is €0.35 Mil.
How does MediPharm Labs' Other Current Receivables compare to ZTS?
MediPharm Labs' Other Current Receivables of €0.35 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on MediPharm Labs and its competitors. MediPharm Labs's current Other Current Receivables is €0.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (FRA:MLZ) is currently considered Fairly Valued. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 3.8% above its estimated fair value. The current Other Current Receivables is €0.35 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For MediPharm Labs (FRA:MLZ), the current Other Current Receivables is €0.35 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediPharm Labs Business Description

Other Exchanges MEDIF:USALABS:Canada
Address 151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.